Slater D E, Mertelsmann R, Koziner B, Higgins C, McKenzie S, Schauer P, Gee T, Straus D, Kempin S, Arlin Z
J Clin Oncol. 1986 Jan;4(1):57-67. doi: 10.1200/JCO.1986.4.1.57.
Fifty-one patients with lymphoblastic lymphoma (LBL) treated with one of five successive intensive chemotherapy protocols for acute lymphoblastic leukemia (ALL) since 1971 were reviewed. The patients were divided into leukemic and nonleukemic groups, and their clinical and laboratory parameters compared. The projected 5-year survival rate for all patients treated with the L10/17 protocols was 45% for both leukemic and nonleukemic LBL. The response to treatment was compared with that of 111 patients with ALL and was nearly identical. Poor prognostic factors were age beyond 30, WBC greater than 50,000/microL, failure to achieve a complete response (CR), and a late CR during induction. Leukemia at presentation, T cell surface markers, and the presence of a mediastinal mass did not adversely affect survival. The use of intensive chemotherapy protocols has proven to be a significant advance in the treatment of LBL.
回顾了自1971年以来采用五种连续强化急性淋巴细胞白血病（ALL）化疗方案之一治疗的51例淋巴母细胞淋巴瘤（LBL）患者。将患者分为白血病组和非白血病组，并比较了他们的临床和实验室参数。接受L10/17方案治疗的所有患者，白血病性和非白血病性LBL的预计5年生存率均为45%。将治疗反应与111例ALL患者的反应进行比较，结果几乎相同。不良预后因素包括年龄超过30岁、白细胞计数大于50,000/微升、未达到完全缓解（CR）以及诱导期出现晚期CR。初诊时的白血病、T细胞表面标志物以及纵隔肿块的存在对生存率没有不利影响。事实证明，使用强化化疗方案是LBL治疗的一项重大进展。
